抑制CD39释放巨噬细胞抗体依赖性细胞吞噬作用对抗B细胞淋巴瘤
本研究检测弥漫大B细胞淋巴瘤(DLBCL)中CD39与CD73表达,发现CD39在非生发中心B细胞样(non-GCB)亚型高表达,而CD73在肿瘤细胞中检测不到。CD39阻断可阻止细胞外ATP降解,以P2X7受体依赖方式增强巨噬细胞对抗体包被淋巴瘤细胞的吞噬,并在体内增强利妥昔单抗和达雷妥尤单抗的抗淋巴瘤效果;CD39抑制剂加入抗CD20与抗CD47联合治疗可显著改善侵袭性B细胞淋巴瘤播散模型生存。
要点
- CD39在non-GCB亚型DLBCL肿瘤中高表达,CD73在肿瘤细胞中检测不到。
- CD39阻断以P2X7受体依赖方式增强巨噬细胞抗体依赖性细胞吞噬(ADCP)。
- CD39抑制剂加入抗CD20与抗CD47联合治疗改善播散模型生存。
核心结论
- 阻止细胞外ATP降解可能是释放巨噬细胞介导抗淋巴瘤免疫的潜在途径。
研究设计与样本
- 研究检测DLBCL组织芯片样本中CD39和CD73表达,并分析细胞外ATP代谢对巨噬细胞介导抗淋巴瘤免疫的影响。
主要发现
- 组织芯片免疫染色显示CD39在non-GCB亚型肿瘤中高表达,在GCB亚型肿瘤中表达程度较低。
- CD73在肿瘤细胞中检测不到。
- CD39药理阻断阻止细胞外ATP降解,以P2X7受体依赖方式增强巨噬细胞对抗体包被淋巴瘤细胞的吞噬。
- CD39抑制增强利妥昔单抗和达雷妥尤单抗等治疗性抗体的体内抗淋巴瘤效果。
- CD39抑制剂加入抗CD20与抗CD47联合治疗显著改善侵袭性B细胞淋巴瘤播散模型生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Redirection of tumor-associated macrophages to eliminate tumor cells holds great promise for overcoming therapeutic resistance to rituximab and other antibody drugs. Here, we determined the expression of ectonucleotidases CD39 and CD73 in diffuse large B-cell lymphoma (DLBCL), and examined the impact of extracellular ATP (eATP) metabolism on macrophage-mediated anti-lymphoma immunity. Immunostaining of tissue microarray samples showed that CD39 (the ecto-enzyme for eATP hydrolysis) was highly expressed in tumors with the non-germinal center B-cell-like (non-GCB) subtype, and to a lesser extent tumors with the GCB subtype. By contrast, the expression of CD73 (the ecto-enzyme for adenosine generation) was undetectable in tumor cells. Pharmacological blockade of CD39 prevented eATP degradation and enhanced engulfment of antibody-coated lymphoma cells by macrophages in a P2X7 receptor-dependent manner, indicating that eATP fueled antibody-dependent cellular phagocytosis (ADCP) activity. Importantly, inhibition of CD39 augmented in vivo anti-lymphoma effects by therapeutic antibodies including rituximab and daratumumab. Furthermore, the addition of a CD39 inhibitor to anti-CD20 and anti-CD47 combination therapy significantly improved survival in a disseminated model of aggressive B-cell lymphoma, supporting the benefit of dual targeting CD39-mediated eATP hydrolysis and CD47-mediated "don't eat me" signal. Together, preventing eATP degradation may be a potential approach to unleash macrophage-mediated anti-lymphoma immunity.
引用
- Casey M, Segawa K, Law SC, et al. Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma. Leukemia. 2022. PMID: 36539557. doi:10.1038/s41375-022-01794-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。